Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Summary

This phase 2 study is designed to evaluate the safety and activity of TH-4000 a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced NSCLC.

Timeline

Start

2015-06

Primary completion

2017-01

Completion

2017-01-31

Outcome

Outcome not reported

Stopped: “Lack of efficacy”

Drugs

Indications